Doses - DISOPYRAMIDE PHOSPHATE

Dogs:

a) 7 - 30 mg/kg q2h PO (Wilcke 1985)
b) For dogs >18kg: 100 mg PO tid-qid (Morgan 1988)
c) 6 - 15 mg/kg PO q8h (Kirk 1986)
d) For ventricular arrhythmias: 11 - 22 mg/kg q8h PO (q12h if using long-acting product).
May use in conjunction with quinidine or procainamide. (Ettinger 1989)
Monitoring Parameters -

1) ECG

2) Blood pressure if possible

3) Symptoms of adverse effects (see above); liver function tests if chronic therapy

4) Serum levels if indicated (lack of efficacy, toxicity)
Therapeutic levels in humans have been reported to be between 2 - 7 micrograms/ml and toxic levels are considered to above 9 micrograms/ml. Levels of up to 7 micrograms/ml may be necessary to treat and prevent the recurrence of refractory ventricular tachycardias.
Client Information - Contact veterinarian if animal has persistent problems with difficult urination, dry mouth, vomiting, constipation, becomes lethargic or depressed, or has difficulty breathing.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Disopyramide Phosphate Capsules 100 mg, 150 mg; Norpace® (Searle), Generic; (Rx)Disopyramide Phosphate Capsules Extended-Release 100 mg, 150 mg; Norpace CR® (Searle);(Rx); Generic (Rx)dl-Methionine - see MethionineDMSO - see Dimethyl Sulfoxide